Talazoparib (BMN 673)

For research use only.

Catalog No.S7048 Synonyms: LT-673

147 publications

Talazoparib (BMN 673) Chemical Structure

CAS No. 1207456-01-6

Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Selleck's Talazoparib (BMN 673) has been cited by 147 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.
Features Most potent and selective PARPi reported thus far.
Targets
PARP1 [1]
(Cell-free assay)
0.57 nM
In vitro

BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. BMN 673 selectively kills cancer cells with BRCA-1 or BRCA-2 mutations. BMN 673 demonstrates single-agent cytotoxicityin BRCA-1 mutant (MX-1, IC50 = 0.3 nM) and BRCA-2 mutant cells (Capan-1, IC50 = 5 nM). In contrast, in MRC-5 normal human fibroblastand other tumor cell lines with wild-type BRCA-1 and BRCA-2 genes, IC50 of BMN 673 ranges between 90 nM and 1.9 μM. [1] In cultured human cancer cells, BMN 673 also significantly enhances the cytotoxic efficacy of both Temozolomide and SN-38. Off-target molecular screening did not identify significant non-specific activity for this class of PARP inhibitors. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BR5FVB1-Akt NEPIV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3RbJMxNjFvMUCwJI5O M17uRVI1NzR6L{eyJIg> NYPBWVRHcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2N{[5O{c,OjZyNEe2PVc9N2F-
BR5FVB1-Akt MkPaRZBweHSxc3nzJGF{e2G7 M2L5XlAvOS1zMECgcm0> NX\uc3gyPzJiaB?= MWXpcoR2[2W|IHHwc5B1d3Orcx?= MmjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEe2PVcoRjJ4MES3Olk4RC:jPh?=
Capan-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\jd4FKSzVyPUG2MlDjiIoEsfMAjVUvPOLCidM1UeKh NYK1c5hNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlQ2QTBpPkK1PFY1PTlyPD;hQi=>
MIA PaCa-2 NHH0WlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTV6LkKz5qCKyrIkgJm4MlHjiIoEtV5CpC=> MnzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6NkS1PVAoRjJ3OE[0OVkxRC:jPh?=
RD NGnMNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjFdVVKSzVyPUiuO{BvVQ>? M{\HfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
Rh41 NH[zcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRThwMTDuUS=> NHfjWlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
Rh18 NXnkTnY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u5e2lEPTB;ND65JI5O NFiwVlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
Rh30 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm0dYZKSzVyPUOxMlEhdk1? Mne5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
BT-12 M{HJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3LWo9KSzVyPvMAjVEtODByIH7N NVPuOHZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
CHLA-266 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfscopKSzVyPvMAjVEtODByIH7N NHnhb4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
TC-71 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TrRWlEPTB;Mz63JI5O NVPuRnN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
CHLA-9 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\Ic2dIUUN3ME24MlIhdk1? M2L2OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
CHLA-10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILVN5pKSzVyPU[3Mlghdk1? MlrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
CHLA-258 M1PzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrWUWhKSzVyPUSuOkBvVQ>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
SJ-GBM2 NE[2R2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f2U2lEPTB;MU[uNkBvVQ>? Ml\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
NB-1643 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HCS2lEPTB;MUiuOEBvVQ>? NGPKWmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
NB-EBc1 MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X5XGlEPTB;MkWuPEBvVQ>? MkXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
CHLA-90 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvrNmtKSzVyPvMAjVEtODByIH7N MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
CHLA-136 M2D2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfYbY9KSzVyPUG0MlIhdk1? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
NALM-6 NFPIcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXRepg1UUN3ME20PUBvVQ>? NXO2RWVbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
COG-LL-317 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jsbWlEPTB;OT60JI5O M1iwWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
RS4;11 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTV{Lk[gcm0> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
MOLT-4 M4jYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF4Lk[gcm0> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
CCRF-CEM M2TXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jQNmlEPTB;Nkm3MlMhdk1? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
Kasumi-1 NYTRWmUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP0VGF4UUN3ME23PFYvOiCwTR?= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
Karpas-299 MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXlV3hbUUN3ME23OU44KG6P MoT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
Ramos-RA1 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XS[mlEPTB;NkiuN{BvVQ>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
DT40 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTRibl2= NFrNNno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1OlgyOyd-MkSzOVY5OTN:L3G+
DU145 NIfBb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[5bpJKUUN3ME2xNUBvVQ>? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3NkixN{c,OjR|NU[4NVM9N2F-
H209 NUTEO4R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwNzDuUS=> NXfYSIxKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwO|c{PTBpPkK0NFc4OzVyPD;hQi=>
H1048 NEP6emFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJwMjDuUS=> NFO3bIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC3O|M2OCd-MkSwO|c{PTB:L3G+
H524 NFjkOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLkWpZKSzVyPUOuNUBvVQ>? NVjl[lZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwO|c{PTBpPkK0NFc4OzVyPD;hQi=>
H1930 NF74fFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEizSFVKSzVyPUSuNUBvVQ>? NX3QfXFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwO|c{PTBpPkK0NFc4OzVyPD;hQi=>
H69 M2j2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\tTWM2OD13LkKgcm0> NVTRb5F7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwO|c{PTBpPkK0NFc4OzVyPD;hQi=>
H2081 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnoOGZ[UUN3ME22MlMhdk1? MmrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyN{ezOVAoRjJ2MEe3N|UxRC:jPh?=
H2107 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17CPWlEPTB;Nz6zJI5O MonnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyN{ezOVAoRjJ2MEe3N|UxRC:jPh?=
H1092 NVzEdGFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLwcGFKSzVyPUiuPUBvVQ>? NInQPYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC3O|M2OCd-MkSwO|c{PTB:L3G+
DMS-79 NWXzZox[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCxTWM2OD17LkOgcm0> NGjGR|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC3O|M2OCd-MkSwO|c{PTB:L3G+
H446 NEH2c5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXtfIFKSzVyPUGzJI5O MkDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyN{ezOVAoRjJ2MEe3N|UxRC:jPh?=
COR-L279 NHvNbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF3IH7N M4rkUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEe3N|UxLz5{NEC3O|M2ODxxYU6=
LoVo M3zFc2Z2dmO2aX;uJIF{e2G7 MkXtN|AhdWmwcx?= MVLFR|UxKD1iMD6wNFI2KM7:TR?= MoTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkGwPVYoRjJ3N{[xNFk3RC:jPh?=
MX1 NX;yU3ExS3m2b4TvfIlkcXS7IHHzd4F6 NYS1OXhbTUN3MDC9JFAvODByMzFOwG0> M2\YUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
LoVo MVjGeY5kfGmxbjDhd5NigQ>? NVHmXJA6OzBibXnudy=> NInoZZZGSzVyIE2gNE4xODJ3MTFOwG0> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
LoVo MWfDfZRwfG:6aXPpeJkh[XO|YYm= NFzpWYoxNjRidV2= NEL4WVE2KGSjeYO= NHfR[GNIUTVyIE2gNE4xODRizszN NFP5RW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
Capan1 NFHi[XVEgXSxdH;4bYNqfHliYYPzZZk> NHuybG1GSzVyIE2gNE4xODVizszN NYLZXlM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
MRC5 MYrDfZRwfG:6aXPpeJkh[XO|YYm= NXTqN3FTTUN3MDC9JFAvOzFizszN M17CdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
MX1 NWnKPGdlTnWwY4Tpc44h[XO|YYm= MlnPNUBu\y:tZx?= NVjieJpjOiBuODDhcoQhOjRiaILz MYrE[YNz\WG|ZTDpckBRSVJibHX2[YwhcW5iYYTofY1q[yCwdT;ueUBud3W|ZTD4[Y5w\3KjZoTl[EB4cXSqIHj1cYFvKE2[MTDj[YxteyCjdDCxJI1oN2upLDDwc{Bi\G2rbnnzeIVz\WRiYYOgd4lv\2ynIHTvd4UhdWWjc4Xy[YQh[W[2ZYKgNkAtQCCjbnSgNlQhcHK|IHL5JGVNUVOD NUPxZow2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
MX1 NX;DcWd4SW62aYT1cY9zKGG|c3H5 MnnNNE4{OyCvZz;r[y=> NH\kUoYzQCCmYYnz NE\zfJFCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBDWkODMTDk[YZq[2mnboSgbJVu[W5iTWixJINmdGy|IIjlco9oemGodHXkJIlvKGG2aIntbYMhdnVxboWgcY92e2ViYYSgNE4{OyCvZz;r[{wheG9icXSgZYRucW6rc4TldoVlKG[xcjCyPEBl[Xm| M3vlUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
MX1 MknsRY51cXS3bX;yJIF{e2G7 M{\QeFAvOTZ3IH3nM4to M{jFUlI5KGSjeYO= MV;BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDCVmNCOSCmZX\pZ4lmdnRiaIXtZY4hVVhzIHPlcIx{KHinbn;ndoFnfGWmIHnuJIF1cHmvaXOgcpUwdnVibX;1d4Uh[XO|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6xOlUhdWdxa3esJJBwKGGmbXnubZN1\XKnZDD0e4lk\SCjIHThfUBnd3JiMkig[IF6ew>? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
MX1 NVvITolJTnWwY4Tpc44h[XO|YYm= NHOxdosxNjN|IH3nM4to NH:5TJpRd3SnboTpZZRqd25ib3[gZ4Fz[m:ybHH0bY4ucW6mdXPl[EB1fW2xcjDndo94fGhiaX7obYJqfGmxbjDv[kBDWkODMTDk[YZq[2mnboSgbJVu[W5iTWixJINmdGy|IIjlco9oemGodHXkJIlvKGG2aIntbYMhdnVxboWgcY92e2ViYYSgNE4{OyCvZz;r[{BxdyCjbnSgZY5qdWGuczD3[ZJmKHS{ZXH0[YQhf2m2aDDjZZJjd3CuYYTpckBifCB|NTDt[{9s\yxiaYCgc44h\GG7IEG= M1m3VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
MDA-MB-436 NHTycXFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NWDVbVZ2PyCmYYnz NVHScpFvUUN3MDC9JFAvODByNzFOwG0> MlvEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OUK5NVYoRjJ6NkmyPVE3RC:jPh?=
Capan1 M2HOTGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MkjjO{Bl[Xm| MlTlTWM2OCB;IECuNFAyQCEQvF2= Mlz3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OUK5NVYoRjJ6NkmyPVE3RC:jPh?=
VC8 NYH6VoZnS3m2b4TvfIlkcXS7IHHzd4F6 NEj0NXA{KGSjeYO= M1P5XWlEPTBiPTCwMlAxPDJizszN MnPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OUK5NVYoRjJ6NkmyPVE3RC:jPh?=
V79 MXTDfZRwfG:6aXPpeJkh[XO|YYm= MonxN{Bl[Xm| MkXGTWM2OCB;IEWuNFEyPCEQvF2= NXjBTnl7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PVI6OTZpPkK4OlkzQTF4PD;hQi=>
Capan1 NUPKcG56TnWwY4Tpc44h[XO|YYm= M4Pm[FAvOSC3TR?= MmjnOEBpenN? NX;sUGdFUW6qaXLpeIlwdiCxZjDQRXJROSCrbjDCVmNCOiCmZX\pZ4lmdnRiaIXtZY4hS2GyYX6xJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKFCDUmCxMWRPSSC2cnHwdIlv\yCjdDCwMlEhfU1iYX\0[ZIhPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NV\4d2p5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PVI6OTZpPkK4OlkzQTF4PD;hQi=>
MDA-MB-436 NYXOe3M4TnWwY4Tpc44h[XO|YYm= MWixJJVO NYjkOpoxPCCqcoO= M3O1N2lvcGmkaYTpc44hd2ZiUFHSVFEhcW5iQmLDRVEh\GWoaXPp[Y51KGi3bXHuJG1FSS2PQj20N|Yh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iUFHSVFEuTE6DIITyZZBxcW6pIHH0JFEhfU1iYX\0[ZIhPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NFX2c|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[5NlkyPid-Mki2PVI6OTZ:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved-PARP / cleaved-caspase3 / γ-H2AX; 

PubMed: 29158830     


Western Blot data testing protein expression after treatment with Olaparib, Niraparib, and Talazoparib on Brca1-deficient cell line in W0069 cells.

pKAP1 / pChk2 / pChk1; 

PubMed: 28947502     


Western blot images (representative from 3 independent experiments) showing the impact of a 24 hour pre-treatment with TAL ± TMZ on DNA damage signaling in U251 (MGMT-low) and T98G (MGMT-high) cells. 

PD-L1; 

PubMed: 28167507     


MDA-MDA-MB-231 and BT549 cells were treated with 10 μM olaparib or 10 nM talazoparib for 24 hours, and subjected to immunoblotting with the indicated antibodies. PD-L1 knockout (K/O) cells were included as a negative control. 

p-ATM; 

PubMed: 30472087     


Western blot analysis of the DNA damage sensors ATM, p-ATM (Ser1981), CHK1, p-CHK1 (Ser317), CHK2 and p-CHK2 (Thr68) in MV4-11 and HL-60 cells. GAPDH served as a loading control.

29158830 28947502 28167507 30472087
Growth inhibition assay
Cell viability; 

PubMed: 29158830     


Measured dose response curve and IC50 of Talazoparib in W780 and W0069 cells.

29158830
Immunofluorescence
cleaved PARP / 53BP1; 

PubMed: 28958991     


Cleaved-PARP and 53BP1 expression. Representative images with 10× objective from high-content imaging of control cells in the left column, and cells treated with veliparib, olaparib, and talazoparib in three right columns. 53BP1 expression is seen in: A, HCC1143; B, MDAMB231; and C, HCC1806. Blue represents nuclear staining and pink foci represent 53BP1 foci. Cleaved-PARP expression is seen in D, HCC1143 and E, HCC1806. Blue represents nuclear staining and green represents cleaved-PARP expression.

RAD51; 

PubMed: 30621214     


(A) MCF7 and (B) MCF7-T cells were treated with either 100 nM tamoxifen (Tamox) or 1 nM talazoparib (Talaz) for 72 h, alone and in combination. 24 h post treatment RAD51 foci formation assay was performed. Scale bar: 20 µm.

28958991 30621214
In vivo In rat pharmacokinetic studies, BMN 673 displays >50% oralbioavailability and pharmacokinetic properties that enable singledaily dosing. In MX-1 xenograft tumor model studies, daily oral dosingof BMN 673 significantly enhances the antitumor effects ofcytotoxic therapies in a dose-dependent manner. [2]

Protocol

Animal Research:

[2]

- Collapse
  • Animal Models: MX-1 model (BRCA-1 deficient)
  • Dosages: 0.33 mg/kg/day, once daily
  • Administration: Oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL warmed (99.9 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 380.35
Formula

 

C19H14F2N6O
 
CAS No. 1207456-01-6
Storage powder
in solvent
Synonyms LT-673
Smiles CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04987931 Not yet recruiting Drug: Talazoparib Breast Cancer Pfizer August 10 2021 --
NCT04991480 Not yet recruiting Drug: ART4215|Drug: Talazoparib Advanced Cancer|Metastatic Cancer|Breast Cancer Artios Pharma Ltd August 2021 Phase 1|Phase 2
NCT04901702 Recruiting Drug: Onivyde|Drug: Talazoparib|Drug: Temozolomide Recurrent Solid Tumor|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Wilms Tumor|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma St. Jude Children''s Research Hospital|Pfizer|Ipsen June 9 2021 Phase 1|Phase 2
NCT04703920 Recruiting Drug: Talazoparib|Drug: Belinostat Metastatic Breast Cancer|Metastatic Castration-resistant Prostate Cancer|Metastatic Ovarian Carcinoma University of Michigan Rogel Cancer Center|Pfizer|Acrotech Biopharma LLC March 4 2021 Phase 1
NCT04672460 Recruiting Drug: TALZENNA capsule|Drug: Talazoparib soft gel capsule Advanced Solid Tumors Pfizer December 21 2020 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Which solvent do you recommend to dilute the inhibitor for in vivo study in mice?

  • Answer:

    BMN673 (S7048) can be dissolved in vehicle (10% DMAc, 6% Solutol, and 84% PBS) according to the paper: http://clincancerres.aacrjournals.org/content/19/18/5003.full. Quote from Method and Material section "Xenograft experiments: BMN 673 (various doses as indicated), or vehicle (10% DMAc, 6% Solutol, and 84% PBS) was administered by oral gavage"

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Talazoparib (BMN 673) | Talazoparib (BMN 673) supplier | purchase Talazoparib (BMN 673) | Talazoparib (BMN 673) cost | Talazoparib (BMN 673) manufacturer | order Talazoparib (BMN 673) | Talazoparib (BMN 673) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID